<?xml version="1.0" encoding="UTF-8"?>
<document id="DDI-DrugBank.d144">
    <sentence id="DDI-DrugBank.d144.s0" text="Concomitant oral administration of ketoconazole (a known inhibitor of CYP3A4 activity in the liver and in the intestinal mucosa) caused an eight-fold increase of the systemic exposure to oral budesonide.">
        <entity id="DDI-DrugBank.d144.s0.e0" charOffset="35-46"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d144.s0.e1" charOffset="192-201"
            type="drug" text="budesonide"/>
        <ddi id="DDI-DrugBank.d144.s0.d0" e1="DDI-DrugBank.d144.s0.e0"
            e2="DDI-DrugBank.d144.s0.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d144.s1" text="If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.">
        <entity id="DDI-DrugBank.d144.s1.e0" charOffset="57-68"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d144.s1.e1" charOffset="71-83"
            type="drug" text="intraconazole"/>
        <entity id="DDI-DrugBank.d144.s1.e2" charOffset="86-94"
            type="drug" text="ritonavir"/>
        <entity id="DDI-DrugBank.d144.s1.e3" charOffset="97-105"
            type="drug" text="indinavir"/>
        <entity id="DDI-DrugBank.d144.s1.e4" charOffset="108-117"
            type="drug" text="saquinavir"/>
        <entity id="DDI-DrugBank.d144.s1.e5" charOffset="120-131"
            type="drug" text="erythromycin"/>
        <entity id="DDI-DrugBank.d144.s1.e6" charOffset="171-180"
            type="drug" text="budesonide"/>
        <ddi id="DDI-DrugBank.d144.s1.d0" e1="DDI-DrugBank.d144.s1.e0"
            e2="DDI-DrugBank.d144.s1.e6" type="advise"/>
        <ddi id="DDI-DrugBank.d144.s1.d1" e1="DDI-DrugBank.d144.s1.e1"
            e2="DDI-DrugBank.d144.s1.e6" type="advise"/>
        <ddi id="DDI-DrugBank.d144.s1.d2" e1="DDI-DrugBank.d144.s1.e2"
            e2="DDI-DrugBank.d144.s1.e6" type="advise"/>
        <ddi id="DDI-DrugBank.d144.s1.d3" e1="DDI-DrugBank.d144.s1.e3"
            e2="DDI-DrugBank.d144.s1.e6" type="advise"/>
        <ddi id="DDI-DrugBank.d144.s1.d4" e1="DDI-DrugBank.d144.s1.e4"
            e2="DDI-DrugBank.d144.s1.e6" type="advise"/>
        <ddi id="DDI-DrugBank.d144.s1.d5" e1="DDI-DrugBank.d144.s1.e5"
            e2="DDI-DrugBank.d144.s1.e6" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d144.s2" text="After extensive intake of grapefruit juice (which inhibits CYP3A4 activity predominantly in the intestinal mucosa), the systemic exposure for oral budesonide increased about two times.">
        <entity id="DDI-DrugBank.d144.s2.e0" charOffset="147-156"
            type="drug" text="budesonide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d144.s3" text="As with other drugs primarily being metabolized through CYP3A4, ingestion of grapefruit or grapefruit juice should be avoided in connection with budesonide administration.">
        <entity id="DDI-DrugBank.d144.s3.e0" charOffset="145-154"
            type="drug" text="budesonide"/>
    </sentence>
</document>
